

**PD-INHIBITOR (NIVOLUMAB) AND IPILIMUMAB FOLLOWED BY NIVOLUMAB VS. VEGF TKI CABOZANTINIB WITH NIVOLUMAB: A PHASE III TRIAL IN METASTATIC UNTREATED RENAL CELL CANCER [PDIGREE]**

**Eligibility Criteria (see Section 3.0)**

**Step 1 Registration Criteria**

Histologic documentation of renal cell carcinoma with clear cell component  
 Metastatic disease  
 Measurable disease  
 Intermediate or poor risk per IDMC criteria  
 CNS disease is allowed, if stable  
 Karnofsky PS  $\geq$  70%  
 Prior Treatment per Section 3.2.6  
 Non-pregnant and non-nursing  
 Age  $\geq$  18 years  
 None of the conditions in Section 3.2.9

**Required Initial Laboratory Values**


Absolute neutrophil count (ANC):  $\geq$  1500/mm<sup>3</sup>  
 Platelet count:  $\geq$  100,000/mm<sup>3</sup>  
 Hemoglobin:  $\geq$  8 g/d  
 Calc. creatinine clearance:  $\geq$  30 mL/min  
 Urine protein  $\leq$  1+ or UPC Ratio  $<$  1  
 Total bilirubin:  $\leq$  1.5 x ULN (except patients with Gilbert's, see Section 3.2.10)  
 AST/ALT:  $\leq$  2.5 x ULN or  $<$  5 x ULN if hepatic

**Step 2 Registration Criteria**

Must have completed at least 1 cycle of ipi/nivo  
 All AEs have resolved to  $\leq$  grade 1  
 $\leq$  80 days from last dose of ipi/nivo

**Schema**

1 cycle = 28 days



Patients with a complete response at 1 year following registration will discontinue treatment. Patients will be followed for 5 years or until death, whichever comes first.

**Please refer to the full protocol text for a complete description of the eligibility criteria and treatment plan.**